Executive Change · Shareholder Vote

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2026 Accendra Health, Inc . (Exact name of registrant as specified in its charter) ​ ​ ​ ​ ​ Virginia 001-09810 ​ 54-1701843 (State or other jurisdiction of (Commission ​ (I.R.S. Employer incorporation or organization) File Number) ​ Identification No.) ​ ​ ​ ​ 4435 Waterfront Drive, Suite 300 , Glen Allen , Virginia ​ ​ 23060 (Address of principal executive ​ ​ ​ offices) ​ ​ (Zip Code) ​ ​ ​ ​ ​ Registrant’s telephone number, including area code (804) 277-4304 Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ ​ ​ ​ Title of each class   ​ ​ ​ Trading Symbol(s)   ​ ​ ​ Name of each exchange on which registered Common Stock, $2 par value per share ​ ACH ​ New York Stock Exchange ​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.below): ​ ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company           ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.           ◻ ​ ​ ​ ​ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 14, 2026 at the 2026 Annual Meeting of Shareholders (the “Annual Meeting”) of Accendra Health, Inc. (the “Company”), the shareholders approved the Accendra Health, Inc. Amended and Restated 2023 Omnibus Incentive Plan (the “Amended and Restated 2023 Plan”) which amends and restates the Owens & Minor, Inc. 2023 Omnibus Incentive Plan (as amended as of March 14, 2024). The description of the Amended and Restated 2023 Plan included in the Company's proxy statement filed with the Securities and Exchange Commission on April 2, 2026 is incorporated herein by reference. Under the terms of the Amended and Restated 2023 Plan, the Board of Directors (the “Board”) has authorized the Our People & Culture Committee of the Board to grant equity and other incentive awards to employees, non-employee directors and consultants. Each equity grant made pursuant thereto will be evidenced by an agreement between the Company and the person named therein. Item 5.07 Submission of Matters to a Vote of Security Holders. On May 14, 2026 at the 2026 Annual Meeting of Shareholders of the Company, the matters described below were voted upon and approved as indicated. There were 76,437,917 shares of common stock entitled to vote at the meeting and 62,134,133 shares were voted in person or by proxy (approximately 81.29% of shares entitled to vote). (1) Election of six directors, each for a one-year term, as follows: ​ Votes ​ Director Votes For Votes Against Abstentions Broker Non- Votes Mark A. Beck 50,962,576 1,294,183 113,704 9,763,670 Gwendolyn M. Bingham 51,120,827 1,136,584 113,052 9,763,670 Kenneth Gardner-Smith 50,944,000 1,312,205 114,258 9,763,670 Stephen W. Klemash 51,165,959 1,090,992 113,512 9,763,670 Teresa L. Kline 51,189,677 1,068,135 112,651 9,763,670 Edward A. Pesicka 48,760,777 3,497,266 112,420 9,763,670 ​ (2) Ratification of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 as follows: ​ Votes Votes For Votes Against Abstentions Broker Non- Votes 61,255,312 693,111 185,710 - ​ ​ (3) Non-binding advisory vote to approve the compensation of our named executive officers as follows: ​ Votes Votes For Votes Against Abstentions Broker Non- Votes 48,137,834 4,098,288 134,341 9,763,670 ​ (4) Approval of the Accendra Health, Inc. Amended and Restated 2023 Omnibus Incentive Plan as follows: ​ Votes Votes For Votes Against Abstentions Broker Non- Votes 50,645,557 1,573,141 151,765 9,763,670 ​ ​ ​ ​ ​ ​ SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ​ ​ ​ ​ ​ ​ ​ ACCENDRA HEALTH, INC. ​ ​ Date: May 15, 2026 By: /s/ Heath H. Galloway ​ Name:   ​ Heath H. Galloway ​ Title: ​ Executive Vice President, General Counsel and Corporate Secretary ​ ​ ​ ​